Invention Grant
- Patent Title: Prodrugs of imidazotriazine compounds as CK2 inhibitors
-
Application No.: US15769113Application Date: 2016-10-19
-
Publication No.: US10550125B2Publication Date: 2020-02-04
- Inventor: Ashok Vinayak Purandare , Kurt Zimmermann , Honghe Wan
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Ellitt Korsen; Hong Liu
- International Application: PCT/US2016/057580 WO 20161019
- International Announcement: WO2017/070135 WO 20170427
- Main IPC: A61K31/53
- IPC: A61K31/53 ; C07D487/04 ; A61P19/02 ; A61P17/06 ; A61P35/02
Abstract:
The invention provides pharmaceutically active compounds of formula (I) and prodrugs thereof. The formula (I) 2-(aminophenylamino)-4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazine derivatives inhibit CK2 protein kinase activity, thereby making them useful for treating cancer, psoriasis and rheumatoid arthritis.
Public/Granted literature
- US20180305364A1 PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS Public/Granted day:2018-10-25
Information query
